QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

SNY

QT74Sanofi
NASDAQ·Healthcare·Drug Manufacturers - General·FR
Latest market price
42.38
-0.12-0.28%
OverviewShort InterestFilings
SNYQT74Sanofi·NASDAQ
OverviewShort InterestFilings
42.38-0.28%
TA
Loading chart...
Screen all →
LLY-1.21%$1098.57JNJ-2.48%$228.39ABBV-2.08%$216.63NVS-2.52%$147.08MRK-1.36%$113.87AZN-1.66%$174.93NVO-0.76%$43.19AMGN-1.19%$337.60
Snapshot
Index-P/E8.53EPS (ttm)2.23
Insider Own-
Shs Outstand1.21B
Perf Week-3.92%
Market Cap101.16BForward P/E8.23EPS next Y5.15Insider Trans-Shs Float-Perf Month-2.69%
Enterprise Value117.76BPEG-EPS next Q1.25Inst Own-Short Float-Perf Quarter-6.53%
Income11.86BP/S1.50EPS this Y116.34%Inst Trans-Short Ratio-Perf Half Y-10.67%
Sales67.52BP/B1.21EPS next Y6.67%ROA8.09%Short Interest-Perf YTD-12.55%
Book/sh69.64P/C4.31EPS next 5Y8.86%ROE14.41%52W High52.68 -19.55%Perf Year-12.11%
Cash/sh5.28P/FCF4.67EPS past 3/5Y-ROIC11.66%52W Low41.86 1.24%Perf 3Y-
Dividend Est.2.42 (5.71%)EV/EBITDA9.44Sales past 3/5Y7.30% 4.34%Gross Margin71.62%Volatility1.18% 1.74%Perf 5Y-
Dividend TTM2.42 (5.71%)EV/Sales1.74EPS Y/Y TTM93.72%Oper. Margin25.09%ATR (14)0.88Perf 10Y-
Dividend Ex-DateMay 04, 2026Quick Ratio0.22Sales Y/Y TTM14.66%Profit Margin17.59%RSI (14)40.48Recom2.67
Dividend Gr. 3/5Y2.41% 4.60%Current Ratio1.01EPS Q/Q17.02%SMA20-3.30%Beta0.42Target Price51.00
Payout46.08%Debt/Eq0.28Sales Q/Q17.99%SMA50-5.30%Rel Volume1.48Prev Close42.50
Employees82,878LT Debt/Eq0.22EarningsJul 30SMA200-10.11%Avg Volume2.77MPrice42.38
IPO DateJul 01, 2002Option/ShortYes / YesEPS/Sales Surpr.3.77% 2.09%Net Debt/EBITDA1.33Volume4,085,190Change-0.28%
Analyst Ratings
DateActionAnalystRatingTarget
May-01-26ReiteratedMorgan StanleyOverweight$56 → $52
Apr-20-26ReiteratedBNP Paribas$50
Jan-16-26DowngradeUBSBuy → Neutral
Jan-06-26DowngradeBarclaysOverweight → Equal Weight
Dec-09-25DowngradeGuggenheimBuy → Neutral
Dec-08-25DowngradeJP MorganOverweight → Neutral
Sep-08-25UpgradeMorgan StanleyEqual Weight → Overweight
Sep-02-25UpgradeDeutsche BankHold → Buy
Aug-08-25UpgradeJP MorganNeutral → Overweight
Jun-02-25ResumedMorgan StanleyEqual Weight$56
Latest News
Jun-18-26
Jun-18-2604:40AM
My Top 5 Dividend Picks For JuneSeekingAlpha
Jun-16-26
Jun-16-2603:19PM
Five International Dividend Growers Your Screen Is DistortingSeekingAlpha
12:40PM
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong FundamentalsChartMill
Jun-15-26
Jun-15-2604:49PM
Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI FirstSeekingAlpha
01:15PM
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric PatientsBenzinga
06:41AM
On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 DiabetesBenzinga
Jun-11-26
Jun-11-2609:09AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga
09:09AM
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst SaysBenzinga
Jun-09-26
Jun-09-2609:59AM
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg ExpansionsSeekingAlpha
Jun-08-26
Jun-08-2602:50AM
Sanofi's Sarclisa Becomes First EU-Approved Anticancer Therapy Via On-Body Injector, Covering All Four Existing Multiple Myeloma IndicationsBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue54,93552,70247,913
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A15,28014,72114,286
Gross Profit39,65537,98133,626
Selling, General and Administrative Excl. Other11,37211,5549,935
Research and Development9,0208,8478,000
Other Operating Expense11,9106,7537,845
Operating Income7,35210,8277,846
Interest Expense584706674
Unusual Expense
———
Non-Operating Income (Expense)-3,4363,154-211
Net Income Before Taxes6,7766,7917,311
Income Taxes1,1431,1771,303
Consolidated Net Income8,6978,8146,015
Net Income From Continuing Operations5,6345,6156,009
Net Income8,6978,8146,015
EPS (Recurring)2.223.612.37
EPS (Basic, Before Extraordinaries)2.223.612.37
EPS (Diluted)2.233.612.37
EBITDA14,67914,07811,937
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio19.0013.42—
Price To Sales Ratio1.862.24—
Gross Margin72.1972.0770.18
Operating Margin13.3820.5416.38
Net Margin15.8316.7212.55
Shares Outstanding2,4082,4412,503
Market Capitalization102,051118,291—
Operating Lease Expense
———
Insider Trading Volume
$47.48$40.48$33.49$26.50$19.50● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR